Showing 20 of 203 recruiting trials for “combined-hepatocellular-carcinoma-and-cholangiocarcinoma”
RecruitingNCT06277531 ↗
Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)
RecruitingNCT06261047 ↗
Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer
👨⚕️ jibo yue, dorctor, Shandong Cancer Hospital and Institute📍 1 site📅 Started Mar 2024View details ↗
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)
HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)
Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation
👨⚕️ Fabrizio Di Benedetto, University of Modena and Reggio Emilia📍 1 site📅 Started Feb 2024View details ↗
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
RecruitingNCT06369480 ↗
Prognostic Factors for Survival in Patients With Cholangiocarcinoma
👨⚕️ Hans-Christian Pommergaard, M.D./Ph.D., Rigshospitalet, Denmark📍 1 site📅 Started Feb 2024View details ↗
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
👨⚕️ Feng Cheng, MD, The First Affiliated Hospital with Nanjing Medical University📍 3 sites📅 Started Jan 2024View details ↗
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA)
👨⚕️ Enrico Gringeri, Prof., Azienda Ospedale Università di Padova📍 1 site📅 Started Jan 2024View details ↗
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
National Liver Cancer Screening Trial
👨⚕️ Amit Singal, MD, MS, University of Texas Southwestern Medical Center📍 18 sites📅 Started Dec 2023View details ↗
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
RecruitingNCT06140134 ↗
Liver Transplantation in Intrahepatic Cholangiocarcinoma
RecruitingNCT05705219 ↗
Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients
👨⚕️ Ahmed El Kaffas, PhD, University of California, San Diego📍 3 sites📅 Started Dec 2023View details ↗
Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
RecruitingNCT06117891 ↗
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →